News about

Cheerleaders: Look Beyond Pharma For Jobs

Thu, 16 May 2013 17:05:16 -0400

Dividend Highlights/Lowlights for May 9

Thu, 09 May 2013 16:42:08 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Kohl’s Corporation (KSS) – up 3% Xerox (XRX) – up 2% AmBev (ABV) – up 2% AbbVie Inc. (ABBV) – up 2% 3M (MMM) – up 2% Lowlights Activision Blizzard, Inc. (ATVI) – down 6% [...]

Dividend Highlights/Lowlights for May 8

Wed, 08 May 2013 16:49:16 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Whole Foods Market (WFM) – up 10% Lowe’s (LOW) – up 5% Baxter International (BAX) – up 3% Agrium (AGU) – up 3.5% Mosaic Co. (MOS) – up 3% Lowlights MercadoLibre (MELI) – down 4% [...]

Florida Won't Protect Biotechs From Competition

Tue, 07 May 2013 13:13:46 -0400

Dividend Highlights/Lowlights for May 2

Thu, 02 May 2013 16:40:03 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Visa Inc (V) – up 6% HollyFrontier Corp (HFC) – up 3% Apple Inc. (AAPL) – up 2% Discover Financial (DFS) – up 2% Exxon Mobil Corporation (XOM) – up 1% Lowlights AbbVie Inc (ABBV) [...]

UPDATE: BMO Capital Raises PT on AbbVie Following 1Q13 Earnings Call

Mon, 29 Apr 2013 10:40:54 -0400

In a report published Monday, BMO Capital Markets analyst Alex Arfaei reiterated a Market Perform rating on AbbVie (NYSE: ABBV), and raised the price target from $43.00 to $47.00.

In the report, Arfaei noted, “Humira continues to offset the weakening of AbbVie's other franchises, such as the lipid and

Market Wrap-Up for Apr.26 (ABBV, EXPE, VFC, GNC, COV, more)

Fri, 26 Apr 2013 16:31:36 -0400

The market headed to another solid close for the trading week. Stocks as well as gold prices have been booking solid gains over the past few days. Plenty of earnings headwinds will continue into next week, as investors look ahead to what the averages will be doing when earnings begin to ease up by mid-May [...]

Key Pfizer Drug in Trouble In Europe

Fri, 26 Apr 2013 14:11:03 -0400

AbbVie Sees Higher Earnings on Strong Humira Sales; Beats Estimates (ABBV)

Fri, 26 Apr 2013 10:19:10 -0400

Pharmaceutical company, AbbVie Inc (ABBV) reported increased profits for its first quarter on Friday, which were helped by strong sales for its arthritis drug, Humira. The North Chicago, IL based company reported first quarter earnings of $968 million, or 60 cents per share, up 9% from $883 million, or 56 cents per share last year. [...]

J.C. Penney, Yahoo are Friday’s stocks to watch

Fri, 26 Apr 2013 05:30:19 -0400

J.C. Penney shares are likely to continue attracting attention on Friday after hedge fund manager George Soros disclosed a significant stake in the retailer.

AbbVie Reports First Earnings Since IPO

Fri, 26 Apr 2013 04:30:00 -0400

DailyFinance.com: AbbVie Inc. (NYSE: ABBV) reported first-quarter 2013 results before markets opened this morning. The pharmaceutical research firm posted adjusted diluted earnings per share (EPS) of $0.68 on revenues of $4.33 billion. Total sales were up 3.7% ... Read more

AbbVie: More Thank a One-Trick Pony?

Wed, 24 Apr 2013 18:14:11 -0400

Dividend Highlights/Lowlights for April 22

Mon, 22 Apr 2013 16:38:26 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Halliburton Company (HAL) – up 6% AbbVie Inc. (ABBV) – up 4% Microsoft (MSFT) – up 4% Hasbro Inc. (HAS) – up 3% International Paper (IP) – up 3% Lowlights Ralph Lauren Corp (RL) – [...]

Market Wrap-Up for Apr.22 (HAS, CAT, ABBV, GE, MCD, KMB, more)

Mon, 22 Apr 2013 16:32:54 -0400

The market was able to shake off the subpar morning session and saw the averages close in the green ahead of what will be another earnings-filled trading week. We had a handful of earnings moving the tape with buyers prevailing to lift names like Hasbro (HAS), Halliburton (HAL) and Caterpillar (CAT), which lowered its profit [...]

Morgan Stanley Upgrades AbbVie to “Overweight” (ABBV)

Mon, 22 Apr 2013 09:14:58 -0400

Morgan Stanley reported on Monday that it has raised its rating on pharmaceutical company, AbbVie Inc (ABBV). The firm has upgraded ABBV from an “Equal-weight” to an “Overweight,” and has given the company a $49 price target. This price target suggests a 12% upside from the stock’s current price of $42.94. Analysts have upgraded the [...]

UPDATE: Morgan Stanley Upgrades AbbVie to Overweight on Higher Humira, Pipeline Estimates

Mon, 22 Apr 2013 08:43:12 -0400

In a report published Monday, Morgan Stanley analyst David Risinger upgraded the rating on AbbVie (NYSE: ABBV) from Equal-Weight to Overweight, and raised the price target from $36.00 to $49.00.

In the report, Risinger noted, “We see multiple call options in the underappreciated pipeline over the next 18-mon. 2015E

AbbVie: One Huge Winner, Lots of Losers

Tue, 16 Apr 2013 19:02:00 -0400

Battle to Ward Off Competition to Biotech Drugs: Progress Report

Wed, 10 Apr 2013 16:25:53 -0400

UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation

Wed, 10 Apr 2013 12:10:40 -0400

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $45.00 to $50.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the

Jefferies Raises Price Targets on Pharmaceutical Stocks (ABBV, ABT, BMY, more)

Wed, 10 Apr 2013 09:32:16 -0400

Jefferies analysts boosted the price target on a number of pharmaceutical companies on Wednesday, holding a positive view of the sector heading into earnings season. The analysts believe a number of the pharma stocks have attractive valuations, adding to the reasons for the bullish view on the sector. Price Target Increases AbbVie Inc. (ABBV) is [...]

Goldman Sachs Boosts Price Target on AbbVie; Reiterates “Buy” Rating (ABBV)

Tue, 09 Apr 2013 11:54:47 -0400

Analysts at Goldman Sachs raised the price target on pharmaceutical company AbbVie Inc (ABBV) on Tuesday due to raised estimates. The analysts maintain a “Buy” rating on ABBV and see shares reaching $45, up from the previous target of $42. This new valuation suggests an 8% upside to Monday’s closing price of $41.77. Goldman Sachs [...]

UPDATE: Goldman Sachs Raises PT on AbbVie on Raised Estimates

Tue, 09 Apr 2013 11:30:54 -0400

In a report published Tuesday, Goldman Sachs analyst Jami Rubin reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $42.00 to $45.00.

In the report, Rubin noted, “We raise our estimates and 12-month price target to $45 on (1) stronger-than-expected Humira scripts during 1Q,

AstraZeneca: Living Down to its Reputation

Fri, 05 Apr 2013 13:52:30 -0400

UPDATE: BMO Capital Markets Raises PT on AbbVie on Increased Synthroid Forecasts

Fri, 05 Apr 2013 10:35:29 -0400

In a report published Friday, BMO Capital Markets analyst Alex Arfaei reiterated a Market Perform rating on AbbVie (NYSE: ABBV), and slightly raised the price target from $42.00 to $43.00.

In the report, Arfaei noted, “We are increasing our Synthroid forecasts following news that Pfizer (PFE) has voluntarily recalled

What to expect from a market that has everything

Fri, 05 Apr 2013 08:01:08 -0400

MarketWatch interviews four market strategists who ranked among the best forecasters in 2012 and who have not modified their original 2013 forecasts in the light of market gains, asking them what they expect for the rest of the year and what advice they’re giving clients.

10 Big-Name Stocks Going Ex-Dividend Next Week (April 8-12)

Thu, 04 Apr 2013 14:00:42 -0400

Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its upcoming dividend payout. For more information, check out Everything Investors Need to Know About Ex-Dividend Dates Below we highlight 10 big-name stocks going ex-dividend for the week of April 8-12, 2013: [...]

3 Obscure Equity ETFs Trouncing SPY

Tue, 26 Mar 2013 12:42:49 -0400

Despite some recent Cyprus-induced hurdles, the S&P 500 is off to a fine start in 2013.

That much is highlighted by the 9.3 percent year-to-date gain for the SPDR S&P 500 (NYSE: SPY) and that does not include a decent showing on Tuesday.

Plenty of well-known sector ETFs have

What Do These Insiders and Institutions Know That You Don't?

Tue, 26 Mar 2013 11:25:09 -0400

These medium- and large-cap companies have experienced a recent surge of insider and institutional buying. While insiders and institutions may exit positions for various reasons, buying sends the signal that these experts expect prices to spike.

American Realty Capital Properties (NASDAQ: ARCP) is an REIT that targets single tenant

Dividend Highlights/Lowlights for March 15

Fri, 15 Mar 2013 16:36:24 -0400

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Morgan Stanley (MS) – up 3.5% Wells Fargo (WFC) – up 3% Discover Financial Services (DFS) – up 3% Apple Inc. (AAPL) – up 3% AbbVie Inc. (ABBV) – up 2.5% Lowlights Abbott Labs (ABT) [...]

AbbVie Opposes Disclosure of Studies on its $9.3 Billion Humira

Mon, 11 Mar 2013 13:00:26 -0400

Bank of America Raises Price Target on AbbVie (ABBV)

Mon, 11 Mar 2013 10:16:11 -0400

Bank of America reported on Monday that it has increased its price target on pharmaceuticals company, AbbVie Inc (ABBV). The firm has reaffirmed a “Buy” rating on ABBV, and has raised the company’s price target from $40 to $42. This price target suggests a 10% upside from the stock’s current price of $37.69. An analyst [...]

Dividend Highlights/Lowlights for March 5

Tue, 05 Mar 2013 16:41:43 -0500

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Vodafone Group (VOD) – up 5% Molson Coors (TAP) – up 4% Best Buy (BBY) – up 3.5% Vornado Realty Trust (VNO) – up 3% MetLife (MET) – up 3% Lowlights Walgreen Company (WAG) – [...]

Dividend Highlights/Lowlights for Feb. 20

Wed, 20 Feb 2013 16:36:17 -0500

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Joy Global Inc. (JOY) – up 3% Digital Realty Trust (DLR) – up 2% Aon Corp (AON) – up 2% Target (TGT) – up 1% AbbVie Inc. (ABBV) – up 1% Lowlights Garmin (GRMN) – [...]

Dividend Highlights/Lowlights for Feb. 14

Thu, 14 Feb 2013 16:34:52 -0500

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights HJ Heinz Co. (HNZ) – up 20% Halliburton Company (HAL) – up 6% Anheuser-Busch InBev (BUD) – up 5% Best Buy (BBY) – up 4% AbbVie Inc. (ABBV) – up 4% Lowlights CenturyLink Inc. (CTL) [...]

24/7 Wall St. Closing Bell — February 7, 2013: Markets Flat to Start, Then Slide (BBRY, MCP, NOK, ABBV, GOOG, FMC, GMCR, IACI, TSO, V, YELP, ALU, BG, CI, MWW, NYT, PM, S, TEVA, ATVI, CSTR, LNKD, RVBD,

Thu, 07 Feb 2013 11:02:00 -0500

DailyFinance.com: U.S. equity markets opened flat this morning, largely due to a slew of data from Europe that essentially cancelled any good news with an equal dollop of bad. U.S. unemployment data came out before the market opened and was a bit worse than expected ... Read more

UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence

Thu, 07 Feb 2013 10:38:48 -0500

Credit Suisse initiated AbbVie (NYSE: ABBV) with a Neutral rating and a $37.00 price target.

Credit Suisse noted, "AbbVie's cross-currents imply minimal stock movement from current price. Growth is modest with 2013-2020 sales and EPS CAGR at 2% and 3% respectively and only 20% revenue contribution from the

Credit Suisse Grows Cautious on Some Big Health Care Stocks (PFE, JNJ, SYK, ABBV)

Thu, 07 Feb 2013 03:35:00 -0500

DailyFinance.com: Have some widely owned health care names hit a wall when it comes to growth and earnings? In a research report issued today, Credit Suisse Group Inc. (NYSE: CS) issues some not very enthusiastic coverage on three large cap pharmaceutical stocks, ... Read more

Top Analyst Upgrades and Downgrades (ABBV, AKAM, BBRY, COCO, DV, GOOG, HLF, JNJ, JCP, MCP, NOK, PFE, SLW, SYK, TE, VCLK, V)

Thu, 07 Feb 2013 03:20:00 -0500

DailyFinance.com: These are some of this Thursday's top analyst upgrades, downgrades and initiations seen from Wall St. research calls. AbbVie Inc. (NYSE: ABBV) started as Neutral at Credit Suisse. Akamai Technologies Inc. (NASDAQ: AKAM) cut to Hold at Jefferies and ... Read more

Jefferies Raises Numbers on AbbVie as Products Squeeze the Competition (ABBV)

Mon, 04 Feb 2013 09:31:49 -0500

On Monday analysts at Jefferies boosted its price target and estimates on pharmaceutical company AbbVie Inc (ABBV) as various drugs, such as Humira, continue to perform well. The analysts increased earning estimates on ABBV and now see shares reaching $45, which suggests a +21% upside to Friday’s closing price. The firm maintained a “Buy” rating [...]

Dividend Stock Added to Recommended List – 2/1

Fri, 01 Feb 2013 09:28:58 -0500

We are adding a dividend stock to our recommended list today. Name Being Added Abbvie (ABBV) is the pharma play recently spun off from Abbott Labs (ABT). The company has debuted with a 4.30% plus dividend yield and recently offered up conservative guidance for 2013, which make the stock’s current valuation a decent risk/reward for [...]

Life aided by buyout talk; Vertex sinks on losses

Wed, 30 Jan 2013 12:31:45 -0500

Life Technologies shares are aided by talk of a buyout while Vertex Pharmaceuticals falls when its fourth-quarter loss is wider than expected.

AbbVie Reports First Outlook as an Independent Company (ABBV)

Wed, 30 Jan 2013 10:20:16 -0500

Pharmaceutical product manufacturer, AbbVie Inc[ABBV]] reported their first earnings outlook on Wedneday after their separation from Abbott. Following the release of their arthritis medication, Humira ABBV has released their first outlook since the separation from Abbott Laboratories(ABT). For FY2013, ABBV is expecting to see earnings in the range of $3.03 to $3.13 per share. Analysts [...]

BofA/Merrill Lynch: Three Reasons to Own Stocks Now (GSK, BMY, SNY, ABBV, PM, MSFT, INTC, BP, KRFT, GE)

Fri, 25 Jan 2013 06:11:00 -0500

DailyFinance.com: Stocks have rallied sharply during January after the last-minute congressional compromise on the fiscal cliff. While the deal was far from perfect, it averted not only a disaster for the U.S. economy, but also a potentially painful hit to risk-asset ... Read more

Dividend Highlights/Lowlights for Jan. 23

Wed, 23 Jan 2013 16:46:58 -0500

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights IBM Corp. (IBM) – up 4% CSX Corp. (CSX) – up 4% AbbVie Inc. (ABBV) – up 4% Whirlpool (WHR) – up 4% The Walt Disney Company (DIS) – up 2% Lowlights Coach, Inc. (COH) [...]

Dividend Highlights/Lowlights for Jan. 22

Tue, 22 Jan 2013 16:34:21 -0500

These were some of the biggest dividend stock performers on the upside and the downside in today’s market action. Highlights Seagate Technology (STX) – up 7% Western Digital (WDC) – up 6% Freeport McMoran (FCX) – up 5% Avon Products (AVP) – up 4% CBS Corporation (CBS) – up 4% Lowlights Canon, Inc. (CAJ) – [...]

AbbVie, Abbott Spinoff, Starts Life Near Top of Pharma Industry’s Dividend-Yield Heap

Thu, 17 Jan 2013 16:18:58 -0500

Stocks To Watch For January 7, 2013

Mon, 07 Jan 2013 02:50:56 -0500

Some of the stocks that may grab investor focus today are:

Wall Street expects Commercial Metals Company (NYSE: CMC) to report its Q1 earnings at $0.17 per share on revenue of $1.89 billion. Commercial Metals shares fell 0.11% to $15.52 in after-hours trading.

Office Depot (NYSE: ODP) announced

AbbVie Declares Inaugural Dividend of $0.40/Share

Fri, 04 Jan 2013 19:59:53 -0500

The board of directors of AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, today declared the Company's first quarterly cash dividend of $0.40 per share. The cash dividend is payable Feb. 15, 2013 to stockholders of record at the close of business on Jan. 15, 2013. AbbVie began trading

Eli Lilly shares climb on improved outlook

Fri, 04 Jan 2013 11:08:32 -0500

Shares of Eli Lilly climb as the company offers a better-than-expected outlook for 2013

UPDATE: Bank of America Merrill Lynch Initiates Coverage on AbbVie with Buy Rating, $40 PT

Fri, 04 Jan 2013 08:38:21 -0500

In a report published Friday, Bank of America Merrill Lynch initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and $40.00 price target.

BofA Merrill Lynch noted, “ABBV is unique among the US Major Pharma companies given its significant product concentration (45% of 2011 revenues were generated by